$23.89
▲ +1.8% Today
as of Jul 22, 09:07 ET
Last 30 days
Recent Press Releases & News
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Mizuho Raises Price Target on Nurix Therapeutics to $34 From $30, Keeps Outperform Rating
Nurix Therapeutics' Roche Deal Seen Driving Long-Term Upside, RBC Capital Markets Says
Overview
52-week range
$8.20
$22
100% of range
Avg surprise (last 1)
+26.8%
Avg reaction (last 1)
+7.9%
100% positive
Latest IV / EM
93%
EM ±21.7% · $23 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Sat Feb 28, 2026 | Feb 2026 | $-0.79 | — | — | — | — | financials |
| Wed Jul 9, 2025 | May/2025 | $-0.52 | $-0.71 | +26.8% | — | +7.9% | earnings |
| Sat May 31, 2025 | May 2025 | $-0.52 | — | — | — | — | financials |
| Fri Feb 28, 2025 | Feb 2025 | $-0.67 | — | — | — | — | financials |
| Sat Aug 31, 2024 | Aug 2024 | $-0.67 | — | — | — | — | financials |
| Fri May 31, 2024 | May 2024 | $-0.71 | — | — | — | — | financials |
| Thu Feb 29, 2024 | Feb 2024 | $-0.76 | — | — | — | — | financials |
| Thu Aug 31, 2023 | Aug 2023 | $-0.68 | — | — | — | — | financials |
| Wed May 31, 2023 | May 2023 | $-0.45 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-92M | — | $-91M | $-48M | $-63M | — | $-55M | $-49M |
| Net income | $-87M | — | $-86M | $-43M | $-56M | — | $-49M | $-45M |
| EPS (diluted) | $-0.79 | — | $-1.03 | $-0.52 | $-0.67 | — | $-0.67 | $-0.71 |
Balance sheet (quarterly)
| Metric | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $71M | $247M | $78M | $84M | $76M | $110M | $99M | $117M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $554M | $607M | $441M | $515M | $564M | $619M | $456M | $450M |
| Total assets | $636M | $688M | $522M | $592M | $615M | $669M | $514M | $511M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $155M | $149M | $150M | $144M | $134M | $142M | $137M | $140M |
| Total equity | $481M | $539M | $372M | $448M | $481M | $527M | $377M | $371M |